JPRN-C000000156CompletedPhase 2
A phase II trial of targeted busulfan and cyclophosphamide conditioning for allogeneic hematopoietic stem cell transplantation for hematological malignancies - Targeted busulfan and cyclophosphamide for allogeneic hematopoietic stem cell transplantation (C-SHOT 0301)
agoya Blood and Marrow Transplantation Group0 sites50 target enrollmentStarted: September 13, 2005Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 16years-old to 65years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) Uncontrollable and active infection (2) Positivity for HIV antibody and/or HBs antigen and/or HCV antibody (3) Graft manipulation such as T cell depletion (4) Impaired organ function (kidney; serum creatinine >2.0 mg/dl, Liver; aspartate aminotransferase more than 5 times high than upper limit or serum bilirubin >2.0mg/dl, heart; left ventricular ejection fraction less than 50%, lung; arterial oxygen saturation < 93% without oxygen inhalation.) (5) History of drug allergy used in the present conditioning or GVHD prophylaxis.
Investigators
Similar Trials
Completed
Not Applicable
Pharmacokinetic studies of Busulfan as part of conditioning therapy prior to allogeneic hematopoietic stem cell transplantation in patients with myelofibrosisD47.1Chronic myeloproliferative diseaseMyelofibrosisDRKS00015217niversitätsklinikum Hamburg-Eppendorf37
Completed
Phase 2
BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's LymphomaNon-hodgkin LymphomaNCT03794167Soonchunhyang University Hospital75
Completed
Phase 2
Phase II Trial of Pentostatin and Targeted BusulfanHematologic MalignanciesNCT00496340H. Lee Moffitt Cancer Center and Research Institute42
Unknown
Phase 1
Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)Multiple MyelomaNCT03795597Loyola University36
Completed
Phase 2
Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan RegimenLeukemiaMyelodysplastic SyndromeNCT00852163Baylor Research Institute20